Opinions differ by expertise in mycobacteriumavium complex disease

Annals of the American Thoracic Society

Volumn 11, Issue 1, 2014, Pages 17-22

  Marras, Theodore K ^a,b   Rebecca Prevots, D ^c   Jamieson, Frances B ^b,d   Winthrop, Kevin L ^e,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d PUBLIC HEALTH ONTARIO   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Mycobacterium avium intracellulare infection; Mycobacterium infections; Nontuberculous; Nontuberculous mycobacteria; Practice guidelines

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONSENSUS; CONTROLLED STUDY; DISEASE DURATION; E-MAIL; FEMALE; HEALTH CARE SYSTEM; HUMAN; INTENSIVE CARE; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PROGNOSIS; RECURRENT DISEASE; REMISSION; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CANADA; CLINICAL COMPETENCE; CONSENSUS; DELAYED DIAGNOSIS; EXPERT TESTIMONY; HUMANS; INFECTIOUS DISEASE MEDICINE; MEDICAL STAFF; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PULMONARY MEDICINE; RECURRENCE; REMISSION, SPONTANEOUS; SURVIVAL RATE; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 84893485748     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201305-136OC     Document Type: Article

References (20)

1. Al-Houqani M, Jamieson F, Mehta M, Chedore P, May K, Marras TK. Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario. Chest 2012;141:190-197.
2. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182: 977-982.
3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
4. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
5. Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can Respir J 2011;18:19-24.
6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. [Published erratum appears in Am J Respir Crit Care Med (7):744-5.
7. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126:566-581. (Pubitemid 39093445)
8. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest 1999;115:1033-1040. (Pubitemid 29193674)
9. Leber A, Marras TK. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J 2011;37:1158-1165.
10. Ballarino GJ, Olivier KN, Claypool RJ, Holland SM, Prevots DR. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009;103:1448-1455.
11. Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008;14:390-396. (Pubitemid 351451385)
12. Hernández-Garduño E, Rodrigues M, Elwood RK. The incidence of pulmonary non-tuberculous mycobacteria in British Columbia, Canada. Int J Tuberc Lung Dis 2009;13:1086-1093.
13. Satyanarayana G, Heysell SK, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001-2009. BMC Infect Dis 2011;11:113.
14. Marras TK, Mehta M, Chedore P, May K, Al Houqani M, Jamieson F. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung 2010;188:289-299.
15. Bickell NA, Earp J, Evans AT, Bernstein SJ. A matter of opinion about hysterectomies: experts' and practicing community gynecologists' ratings of appropriateness. Am J Public Health 1995;85:1125-1128.
16. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown MR, Chernick M, Steagall WK, Glasgow CG, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066-1074.
17. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575-583.
18. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195-198. (Pubitemid 36920584)
19. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-138. (Pubitemid 44835234)
20. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007;74:394-400. (Pubitemid 47093151)